Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma

Daratumumab, a human immunoglobulin G1 kappa monoclonal antibody that targets CD38, is currently approved as monotherapy and in varying combinations with approved anti-myeloma regimens in both newly diagnosed multiple myeloma and relapsed refractory multiple myeloma. Originally developed for intrave...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ther Adv Hematol
Hlavní autoři: Sanchez, Larysa, Richter, Joshua, Cho, Hearn Jay, Jagannath, Sundar, Madduri, Deepu, Parekh, Samir, Richard, Shambavi, Tam, Lowena, Verina, Daniel, Chari, Ajai
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2021
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841854/
https://ncbi.nlm.nih.gov/pubmed/33613930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720987075
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky